Free Trial
→ Trump’s Bitcoin Reserve is No Accident… (From Crypto 101 Media) (Ad) Buy TRML Stock  Free TRML Stock Alerts

Tourmaline Bio (TRML) Financials

Tourmaline Bio logo
$14.88 -1.32 (-8.12%)
As of 03:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Tourmaline Bio

Annual Income Statements for Tourmaline Bio

This table shows Tourmaline Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders		 -73 -42 -20
Consolidated Net Income / (Loss)		 -73 -42 -20
Net Income / (Loss) Continuing Operations		 -73 -42 -20
Total Pre-Tax Income 		-90 -45 -20
Total Operating Income		 -90 -45 -20
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 90 45 20
Selling, General & Admin Expense		 23 13 2.18
Research & Development Expense		 67 32 18
Total Other Income / (Expense), net		 0.00 0.00 0.00
Other Gains / (Losses), net		 17 3.29 0.00
Basic Earnings per Share		 ($2.89) ($8.87) ($22.46)
Weighted Average Basic Shares Outstanding		 25.35M 4.75M 877K
Diluted Earnings per Share		 ($2.89) ($8.87) ($22.46)
Weighted Average Diluted Shares Outstanding		 25.35M 4.75M 877K
Weighted Average Basic & Diluted Shares Outstanding		 25.69M 25.65M 42.02M

Quarterly Income Statements for Tourmaline Bio

This table shows Tourmaline Bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -22 -20 -17 -13 -13 -5.59 -16 -7.50 36 -19
Consolidated Net Income / (Loss)		 -22 -20 -17 -13 -13 -5.59 -16 -7.50 36 -19
Net Income / (Loss) Continuing Operations		 -22 -20 -17 -13 -13 -5.59 -16 -7.50 36 -19
Total Pre-Tax Income 		-39 -20 -17 -13 -15 -6.64 -16 -7.50 36 -19
Total Operating Income		 -26 -24 -22 -18 -15 -6.64 -16 -7.50 37 -20
Total Operating Expenses		 26 24 22 18 15 6.64 16 7.50 -37 20
Selling, General & Admin Expense		 5.26 5.11 6.24 6.14 6.88 2.88 1.92 1.37 -12 4.84
Research & Development Expense		 21 19 16 11 8.02 3.76 14 6.14 -25 15
Total Other Income / (Expense), net		 -13 4.26 4.48 4.21 -0.25 0.00 0.25 0.00 -1.21 0.73
Basic Earnings per Share		 ($0.88) ($0.78) ($0.68) ($0.55) $20.86 ($5.16) ($16.29) ($8.28) ($16.98) ($4.59)
Weighted Average Basic Shares Outstanding		 25.35M 25.77M 25.72M 24.08M 4.75M 1.08M 990K 906K 877K 4.14M
Diluted Earnings per Share		 ($0.88) ($0.78) ($0.68) ($0.55) $20.86 ($5.16) ($16.29) ($8.28) ($16.98) ($4.59)
Weighted Average Diluted Shares Outstanding		 25.35M 25.77M 25.72M 24.08M 4.75M 1.08M 990K 906K 877K 4.14M
Weighted Average Basic & Diluted Shares Outstanding		 25.69M 25.64M 25.64M 25.65M 25.65M 20.34M 42.76M 42.17M 42.02M 41.72M

Annual Cash Flow Statements for Tourmaline Bio

This table details how cash moves in and out of Tourmaline Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents		 -110 132 8.32
Net Cash From Operating Activities		 -77 -28 -6.46
Net Cash From Continuing Operating Activities		 -77 -28 -6.46
Net Income / (Loss) Continuing Operations		 -73 -42 -20
Consolidated Net Income / (Loss)		 -73 -42 -20
Depreciation Expense		 0.04 0.03 0.01
Amortization Expense		 -7.59 -0.52 0.00
Non-Cash Adjustments To Reconcile Net Income		 6.66 15 12
Changes in Operating Assets and Liabilities, net		 -3.15 -0.17 0.90
Net Cash From Investing Activities		 -194 3.84 -5.07
Net Cash From Continuing Investing Activities		 -194 3.84 -5.07
Purchase of Property, Plant & Equipment		 -0.01 -0.06 -0.07
Purchase of Investments		 -366 -17 0.00
Sale and/or Maturity of Investments		 172 21 0.00
Net Cash From Financing Activities		 161 157 20
Net Cash From Continuing Financing Activities		 161 157 20
Repurchase of Common Equity		 -0.00 0.00 -
Issuance of Debt		 0.00 70 0.25
Issuance of Preferred Equity		 0.00 92 20
Issuance of Common Equity		 161 0.00 0.00
Other Financing Activities, net		 0.00 -5.57 0.00

Quarterly Cash Flow Statements for Tourmaline Bio

This table details how cash moves in and out of Tourmaline Bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -4.50 -35 -28 -42 63 -9.04 83 -3.82 8.47 -7.05
Net Cash From Operating Activities		 -21 -23 -18 -15 -9.35 -5.40 -9.54 -3.79 41 -13
Net Cash From Continuing Operating Activities		 -21 -23 -18 -15 -9.35 -5.40 -9.54 -3.79 41 -13
Net Income / (Loss) Continuing Operations		 -22 -20 -17 -13 -13 -5.59 -16 -7.50 36 -19
Consolidated Net Income / (Loss)		 -22 -20 -17 -13 -13 -5.59 -16 -7.50 36 -19
Depreciation Expense		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 -1.02 0.37
Amortization Expense		 -1.97 -2.15 -2.29 -1.18 -0.52 -0.06 0.03 0.03 0.04 -0.33
Non-Cash Adjustments To Reconcile Net Income		 1.78 1.72 1.79 1.37 4.26 0.79 9.26 0.39 4.02 3.28
Changes in Operating Assets and Liabilities, net		 1.53 -2.85 -0.03 -1.81 -0.20 -0.55 -2.70 3.28 1.83 2.27
Net Cash From Investing Activities		 16 -12 -10 -189 3.89 -0.02 -0.01 -0.02 -52 6.30
Net Cash From Continuing Investing Activities		 16 -12 -10 -189 3.89 -0.02 -0.01 -0.02 -52 6.30
Purchase of Property, Plant & Equipment		 -0.01 - - 0.00 -0.00 -0.02 -0.01 -0.02 2.71 -0.34
Purchase of Investments		 -20 -88 -43 -216 -17 - - 0.00 141 -53
Sale and/or Maturity of Investments		 36 76 32 27 21 - - 0.00 -190 59
Net Cash From Financing Activities		 -0.00 -0.00 - 161 68 -3.62 92 0.00 20 0.07
Net Cash From Continuing Financing Activities		 -0.00 -0.00 - 161 68 -3.62 92 0.00 20 0.07
Repurchase of Common Equity		 -0.00 - - - 3.39 - - - - -

Annual Balance Sheets for Tourmaline Bio

This table presents Tourmaline Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets		 309 210 9.10
Total Current Assets		 269 209 8.31
Cash & Equivalents		 31 141 8.26
Short-Term Investments		 228 62 0.00
Prepaid Expenses		 11 5.92 0.05
Plant, Property, & Equipment, net		 0.06 0.09 0.08
Total Noncurrent Assets		 40 1.34 0.71
Long-Term Investments		 37 0.00 -
Other Noncurrent Operating Assets		 3.47 1.34 0.71
Total Liabilities & Shareholders' Equity		 309 210 9.10
Total Liabilities		 8.95 5.25 1.71
Total Current Liabilities		 8.91 5.00 1.36
Accounts Payable		 3.58 1.07 0.40
Accrued Expenses		 5.10 3.71 0.80
Other Current Liabilities		 0.23 0.22 0.16
Total Noncurrent Liabilities		 0.04 0.25 0.34
Other Noncurrent Operating Liabilities		 0.04 0.25 0.34
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 300 205 -20
Total Preferred & Common Equity		 300 205 -20
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 300 205 -20
Common Stock		 435 267 0.20
Retained Earnings		 -135 -62 -20
Accumulated Other Comprehensive Income / (Loss)		 0.30 0.07 0.00

Quarterly Balance Sheets for Tourmaline Bio

This table presents Tourmaline Bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 328 345 359 151 159 173 207
Total Current Assets		 294 298 300 151 156 169 198
Cash & Equivalents		 35 70 98 67 18 24 18
Short-Term Investments		 247 219 195 80 134 142 175
Prepaid Expenses		 12 8.59 7.04 4.02 3.96 3.05 4.26
Plant, Property, & Equipment, net		 0.06 0.07 0.08 0.00 0.23 2.58 5.46
Total Noncurrent Assets		 35 47 59 0.01 2.44 1.16 2.95
Long-Term Investments		 32 45 57 - - - -
Other Noncurrent Operating Assets		 2.14 1.72 1.76 0.01 2.44 1.16 2.95
Total Liabilities & Shareholders' Equity		 328 345 359 151 159 173 207
Total Liabilities		 7.38 6.51 5.03 8.19 11 11 12
Total Current Liabilities		 7.28 6.36 4.83 8.11 10 10 9.17
Accounts Payable		 2.05 2.39 1.94 0.14 2.93 3.38 2.13
Accrued Expenses		 5.00 3.75 2.67 7.29 6.35 6.04 6.13
Other Current Liabilities		 0.23 0.22 0.22 0.68 0.85 0.75 0.91
Total Noncurrent Liabilities		 0.10 0.15 0.20 0.08 0.56 0.70 2.51
Other Noncurrent Operating Liabilities		 0.10 0.15 0.20 0.08 0.56 0.70 2.51
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 321 338 354 143 148 162 195
Total Preferred & Common Equity		 321 338 354 143 148 162 195
Preferred Stock		 0.00 0.00 0.00 - - - -
Total Common Equity		 321 338 354 143 148 162 195
Common Stock		 433 432 430 352 351 349 342
Retained Earnings		 -113 -93 -75 -209 -202 -187 -146
Accumulated Other Comprehensive Income / (Loss)		 0.82 -0.45 -0.25 -0.12 -0.21 -0.30 -1.22

Annual Metrics And Ratios for Tourmaline Bio

This table displays calculated financial ratios and metrics derived from Tourmaline Bio's official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -111.96% -133.04% 57.61%
EBIT Growth		 -97.61% -130.49% 58.53%
NOPAT Growth		 -97.61% -130.49% 58.53%
Net Income Growth		 -73.80% -113.82% 58.81%
EPS Growth		 67.42% 60.51% -1,269.51%
Operating Cash Flow Growth		 -175.14% -334.83% 83.85%
Free Cash Flow Firm Growth		 -89.50% -146.61% 58.04%
Invested Capital Growth		 144.67% 341.73% 25.56%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -14.56% -938.78% 71.79%
EBIT Q/Q Growth		 -13.85% -805.99% 72.27%
NOPAT Q/Q Growth		 -13.85% -594.19% 72.27%
Net Income Q/Q Growth		 -14.61% -753.79% 71.70%
EPS Q/Q Growth		 -115.33% 81.01% -341.26%
Operating Cash Flow Q/Q Growth		 -17.55% -228.81% 88.63%
Free Cash Flow Firm Q/Q Growth		 0.24% -400.02% 71.72%
Invested Capital Q/Q Growth		 -23.38% 150.39% -186.67%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 81.59% 92.77% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -28.99% -39.66% -15.75%
Cash Return on Invested Capital (CROIC)		 -1,827.04% -1,661.52% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -28.99% -34.59% -14.04%
Return on Equity Simple (ROE_SIMPLE)		 -24.40% -20.54% 99.84%
Net Operating Profit after Tax (NOPAT)		 -63 -32 -14
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.18% -9.79% -4.69%
Return On Investment Capital (ROIC_SIMPLE)		 -20.93% -15.50% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -90 -45 -20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -97 -46 -20
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.73 2.60 0.00
Price to Tangible Book Value (P/TBV)		 1.73 2.60 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 44.00 157.56 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -0.99 -0.99 -1.01
Leverage Ratio		 1.03 1.03 1.04
Compound Leverage Factor		 1.03 1.03 1.04
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 366.90%
Common Equity to Total Capital		 100.00% 100.00% -266.90%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 34.30 60.85 5.68
Noncontrolling Interest Sharing Ratio		 0.00% 12.77% 10.84%
Liquidity Ratios		 - - -
Current Ratio		 30.18 41.76 6.10
Quick Ratio		 28.99 40.57 6.06
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -66 -35 -14
Operating Cash Flow to CapEx		 -858,477.78% -50,144.64% -9,497.06%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 5.12 2.09 -0.87
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 3.03 2.96 0.30
Enterprise Value (EV)		 225 329 61
Market Capitalization		 520 532 43
Book Value per Share		 $11.70 $10.08 ($0.47)
Tangible Book Value per Share		 $11.70 $10.08 ($0.47)
Total Capital		 300 205 7.39
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -295 -203 -8.26
Capital Expenditures (CapEx)		 0.01 0.06 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1.63 0.92 -1.31
Debt-free Net Working Capital (DFNWC)		 260 204 6.95
Net Working Capital (NWC)		 260 204 6.95
Net Nonoperating Expense (NNE)		 10 10 5.91
Net Nonoperating Obligations (NNO)		 -295 -203 -8.26
Total Depreciation and Amortization (D&A)		 -7.56 -0.49 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($2.89) ($8.87) ($17.90)
Adjusted Weighted Average Basic Shares Outstanding		 25.35M 4.75M 4.12M
Adjusted Diluted Earnings per Share		 ($2.89) ($8.87) ($17.90)
Adjusted Weighted Average Diluted Shares Outstanding		 25.35M 4.75M 4.12M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 25.69M 25.65M 4.20M
Normalized Net Operating Profit after Tax (NOPAT)		 -63 -32 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.01% 0.00% 0.00%

Quarterly Metrics And Ratios for Tourmaline Bio

This table displays calculated financial ratios and metrics derived from Tourmaline Bio's official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -80.31% -233.35% -22.83% -94.02% -142.82% 66.29% 10.39% 58.36% 354.18% -54.99%
EBIT Growth		 -73.31% -203.73% -8.42% -77.43% -140.30% 66.62% 12.41% 59.26% 356.82% -52.42%
NOPAT Growth		 -73.31% -267.88% -34.18% -133.50% -128.21% 66.49% 11.08% 59.26% 466.88% -51.82%
Net Income Growth		 -72.34% -260.88% -8.42% -77.43% -136.18% 70.59% 10.87% 58.91% 350.44% -46.91%
EPS Growth		 -104.22% 84.88% 95.83% 93.36% 222.85% -12.42% -3,602.27% -1,740.00% -4,453.85% -1,334.38%
Operating Cash Flow Growth		 -123.34% -334.47% -88.73% -293.64% -123.08% 59.81% 44.79% 76.71% 512.30% -32.56%
Free Cash Flow Firm Growth		 -57.63% -5,710.28% -519.93% -2,920.18% -136.50% 103.57% 75.55% 95.16% 452.69% -38.83%
Invested Capital Growth		 144.67% 260.89% 195.11% 194.15% 341.73% -515.83% -212.12% -914.77% 25.56% 9.07%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -24.42% -12.91% -36.49% -113.88% -130.04% 58.40% -115.61% -120.75% 281.10% -10.59%
EBIT Q/Q Growth		 -27.90% -15.38% -31.37% -37.80% -124.15% 58.81% -115.00% -120.30% 285.66% -8.07%
NOPAT Q/Q Growth		 -5.60% -11.23% -25.43% -39.01% -124.15% 59.43% -118.26% -114.21% 366.29% -7.65%
Net Income Q/Q Growth		 -10.20% -15.38% -31.37% -15.97% -130.76% 65.34% -115.00% -121.03% 287.60% -5.06%
EPS Q/Q Growth		 -12.82% -14.71% -23.64% -103.17% 504.26% 68.32% -96.74% 51.24% -269.93% -943.18%
Operating Cash Flow Q/Q Growth		 10.90% -30.19% -20.67% -235.41% -73.33% 43.44% -151.68% -109.35% 401.85% 22.30%
Free Cash Flow Firm Q/Q Growth		 24.50% -19.78% -15.52% -71.41% -2,787.09% 113.24% -462.81% -101.82% 362.58% 9.28%
Invested Capital Q/Q Growth		 -23.38% 72.49% 0.73% 83.79% 150.39% -1.97% 0.29% -371.91% -186.67% -72.51%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 57.37% 100.00% 100.00% 100.00% 85.25% 84.16% 100.00% 100.00% 99.78% 99.59%
Interest Burden Percent		 150.19% 100.00% 100.00% 100.00% 101.65% 100.00% 100.00% 100.00% 96.73% 95.92%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -28.99% -27.54% -20.25% -18.58% -39.66% 3.82% -3.89% -4.61% -15.75% -30.90%
Cash Return on Invested Capital (CROIC)		 -1,827.04% -988.44% -1,308.59% -1,215.76% -1,661.52% 0.00% 0.00% 0.00% 0.00% -5,207.63%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -28.99% -27.54% -20.25% -18.58% -34.59% 3.82% -3.89% -4.61% -14.04% -30.90%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -19.90% -14.57% -13.54% 0.00% 4.51% -4.70% -5.53% 0.00% -35.72%
Net Operating Profit after Tax (NOPAT)		 -18 -17 -15 -12 -10 -4.65 -11 -5.25 37 -14
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.68% -1.33% -0.87% -0.41% -2.35% -0.55% -2.60% -1.15% -1.02% -2.29%
Return On Investment Capital (ROIC_SIMPLE)		 -6.02% - - - -5.08% - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -26 -20 -17 -13 -15 -6.64 -16 -7.50 37 -20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -28 -22 -20 -14 -15 -6.70 -16 -7.46 36 -20
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.73 2.05 0.98 1.66 2.60 0.84 0.86 0.49 0.00 0.56
Price to Tangible Book Value (P/TBV)		 1.73 2.05 0.98 1.66 2.60 0.84 0.86 0.49 0.00 0.56
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 18.65 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 5.36% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 44.00 51.65 0.00 61.67 157.56 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.99 -0.99 -1.00 -1.00 -0.99 -1.01 -1.00 -1.01 -1.01 -1.00
Leverage Ratio		 1.03 1.03 1.04 1.03 1.03 1.06 1.06 1.06 1.04 1.04
Compound Leverage Factor		 1.54 1.03 1.04 1.03 1.05 1.06 1.06 1.06 1.01 1.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 366.90% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -266.90% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 34.99 53.97 30.87 70.63 61.33 7.86 6.19 3.80 26.23 5.42
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 12.77% 0.00% 0.00% 0.00% 10.84% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 30.18 40.33 46.87 62.17 41.76 18.64 15.41 16.59 6.10 21.61
Quick Ratio		 28.99 38.70 45.52 60.71 40.57 18.14 15.02 16.29 6.06 21.15
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -21 -28 -23 -20 -13 0.50 -3.76 -0.67 37 -14
Operating Cash Flow to CapEx		 -232,100.00% 0.00% 0.00% 0.00% -467,650.00% -31,741.18% -73,392.31% -15,795.83% 0.00% -3,937.54%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 5.12 6.68 3.87 3.84 2.09 -4.15 -4.07 -4.08 -0.87 1.00
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 3.03 11 7.94 7.93 2.96 -5.15 -7.70 -4.58 0.30 0.08
Enterprise Value (EV)		 225 345 -4.60 237 329 -27 -24 -87 61 -84
Market Capitalization		 520 659 330 587 532 120 128 79 43 110
Book Value per Share		 $11.70 $12.52 $13.19 $13.81 $10.08 $3.34 $3.52 $3.88 ($0.47) $4.67
Tangible Book Value per Share		 $11.70 $12.52 $13.19 $13.81 $10.08 $3.34 $3.52 $3.88 ($0.47) $4.67
Total Capital		 300 321 338 354 205 143 148 162 7.39 195
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -295 -314 -334 -350 -203 -147 -153 -166 -8.26 -194
Capital Expenditures (CapEx)		 0.01 0.00 0.00 0.00 0.00 0.02 0.01 0.02 -2.71 0.34
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1.63 4.58 2.23 2.21 0.92 -4.08 -6.43 -7.13 -1.31 -4.91
Debt-free Net Working Capital (DFNWC)		 260 287 292 295 204 143 146 159 6.95 189
Net Working Capital (NWC)		 260 287 292 295 204 143 146 159 6.95 189
Net Nonoperating Expense (NNE)		 4.17 3.07 2.11 1.05 2.48 0.94 4.67 2.25 1.29 5.13
Net Nonoperating Obligations (NNO)		 -295 -314 -334 -350 -203 -147 -153 -166 -8.26 -194
Total Depreciation and Amortization (D&A)		 -1.96 -2.14 -2.28 -1.17 -0.51 -0.05 0.04 0.04 -0.98 0.04
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.88) ($0.78) ($0.68) ($0.55) $20.86 ($1.64) ($3.50) ($5.40) ($169.80) ($4.60)
Adjusted Weighted Average Basic Shares Outstanding		 25.35M 25.77M 25.72M 24.08M 4.75M 4.27M 4.22M 4.18M 87.70K 4.14M
Adjusted Diluted Earnings per Share		 ($0.88) ($0.78) ($0.68) ($0.55) $20.86 ($1.64) ($3.50) ($5.40) ($169.80) ($4.60)
Adjusted Weighted Average Diluted Shares Outstanding		 25.35M 25.77M 25.72M 24.08M 4.75M 4.27M 4.22M 4.18M 87.70K 4.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 25.69M 25.64M 25.64M 25.65M 25.65M 20.34M 4.28M 4.22M 4.20M 4.17M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -17 -15 -12 -10 -4.65 -11 -5.25 26 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Tourmaline Bio's Financials

When does Tourmaline Bio's fiscal year end?

According to the most recent income statement we have on file, Tourmaline Bio's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Tourmaline Bio's net income changed over the last 2 years?

Tourmaline Bio's net income appears to be on an upward trend, with a most recent value of -$73.21 million in 2024, rising from -$19.70 million in 2022. The previous period was -$42.12 million in 2023. View Tourmaline Bio's forecast to see where analysts expect Tourmaline Bio to go next.

What is Tourmaline Bio's operating income?
Tourmaline Bio's total operating income in 2024 was -$89.73 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $89.73 million
How has Tourmaline Bio revenue changed over the last 2 years?

Over the last 2 years, Tourmaline Bio's total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Tourmaline Bio have?

Tourmaline Bio's total liabilities were at $8.95 million at the end of 2024, a 70.4% increase from 2023, and a 424.9% increase since 2022.

How much cash does Tourmaline Bio have?

In the past 2 years, Tourmaline Bio's cash and equivalents has ranged from $8.26 million in 2022 to $140.73 million in 2023, and is currently $30.51 million as of their latest financial filing in 2024.

How has Tourmaline Bio's book value per share changed over the last 2 years?

Over the last 2 years, Tourmaline Bio's book value per share changed from -0.47 in 2022 to 11.70 in 2024, a change of -2,574.4%.


Related Companies

This page (NASDAQ:TRML) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored